Recombinant Human Galectin-3 Protein, Low Endotoxin

Name: Recombinant Human Galectin-3 Protein, Low Endotoxin
Brand: Beta LifeScience
SKU: BLPSN-2193
Availability: InStock

Collections: Other recombinant proteins, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag	N/A
Host Species	Human, Low Endotoxin
Accession	P17931
Synonym	CBP35, GAL3, GALBP, GALIG, L31, LGALS2, MAC2
Background	LGALS3, a member of the lectin family, has an important role in tumor progression through inhibition of apoptosis.The galectin-3 gene (LGALS3) encodes a beta-galactose binding lectin. LGALS3 expression is associated with neoplastic transformation and with differentiation of monocytes to macrophages. Galectin-3 is a beta-galactoside-binding lectin which is involved in modulating inflammation and apoptosis. Elevated expression of galectin-3 has been demonstrated in synovium of rheumatoid arthritis (RA).
Description	A DNA sequence encoding the human Galectin3 (P17931) (Met 1-Ile 250) was expressed and purified.
Source	E.coli
Predicted N Terminal	Met 1
AA Sequence	Met 1-Ile 250
Molecular Weight	The recombinant human Galectin3 consisting of 250 a.a. and has a calculated molecular mass of 26.1 kDa. It migrates as an approximately 30 kDa band in SDS-PAGE under reducing conditions.
Purity	>97% as determined by SDS-PAGE
Endotoxin	< 5 EU per 1 mg of the protein as determined by the LAL method
Bioactivity	Measured by its ability to agglutinate human red blood cells. The ED50 for this effect is typically 3-15 ug/ml.
Formulation	Lyophilized from sterile PBS, pH 7.4.
Stability	The recombinant proteins are stable for up to 1 year from date of receipt at -70°C.
Usage	For Research Use Only
Storage	Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Target Details

Target Function	Galactose-specific lectin which binds IgE. May mediate with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. Together with DMBT1, required for terminal differentiation of columnar epithelial cells during early embryogenesis. In the nucleus: acts as a pre-mRNA splicing factor. Involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells. Together with TRIM16, coordinates the recognition of membrane damage with mobilization of the core autophagy regulators ATG16L1 and BECN1 in response to damaged endomembranes.
Subcellular Location	Cytoplasm. Nucleus. Secreted.
Database References	HGNC: 6563 OMIM: 153619 KEGG: hsa:3958 STRING: 9606.ENSP00000254301 UniGene: Hs.531081
Tissue Specificity	A major expression is found in the colonic epithelium. It is also abundant in the activated macrophages. Expressed in fetal membranes.

Gene Functions References

results demonstrate that human resting NK cells express Gal-3 at both gene and protein levels and that the Gal-3 expression can be modulated upon cytokine stimulation. In the same cells, Gal-3 always localizes intracellularly and functionally correlates with the degree of NK cell degranulation. PMID: 29248489
Interaction between galectin-3 and its potential inhibitor, bergenin, was studied using computational methods. PMID: 30276553
It has been reported that the Galectin-3/NuMA interaction is functionally important for the spindle pole organization; spindle pole cohesion requires glycosylation-mediated localization of NuMA. PMID: 28469279
The Mac-2-binding protein glycosylation isomer (M2BPGi), which is also known as Wisteria floribunda agglutinin-positive human Mac-2-binding protein, was recently established as a glycol-biomarker of liver fibrosis in patients with chronic hepatitis C with a unique fibrosis-related glycoalteration. PMID: 30128700
Higher plasma galectin-3 levels were associated with an elevated risk of developing incident chronic kidney disease, particularly among those with hypertension. PMID: 28865675
Pre-interventional plasma Galectin-3 levels are associated with left ventricular reverse remodeling and with clinical outcome after percutaneous mitral valve repair. PMID: 29678512
Galectin-3 is significantly associated with functional capacity, cardiac function and adverse cardiovascular events in adults with congenital heart defects. PMID: 28942393
Gene expression was analyzed for miR-1, miR-21, and galectin-3 in hypertensive patients with symptomatic heart failure and left ventricular hypertrophy. PMID: 29905364
Serum expression of miR-1 and miR-21, and the concentration of gal-3 in systolic heart failure patients with different degrees of left ventricular dilatation. PMID: 29905365
Serum galectin-3 is associated with coronary atherosclerosis and obstructive sleep apnoea syndrome (OSAS) severity in OSAS patients. PMID: 28150280
Study demonstrates that mesenchymal stromal cells (MSC)-derived LGALS3 may be critical for important biological pathways for MSC homeostasis and for regulating AML cell localization and survival in the leukemia microenvironmental niche. PMID: 29655803
Low expression of galectin-3 was detected in all patients with malignant gastrointestinal tumors irrespective of the presence of eosinophilia. PMID: 29926280
These findings highlight a new role for Galectin 3 as a non-classic RNA-binding protein that regulates MUC4 mRNA post-transcriptionally. PMID: 28262838
Galectin-3 is superior to sST2 in distinguishing HFpEF from controls and HFrEF. PMID: 30039808
erum Gal-3 levels were significantly higher in breast cancer (BC) patients and did not significantly differ according to clinical and tumoral characteristics of patients. Furthermore, there was no difference in Gal-3 levels between breast patients with and without metastatic disease. PMID: 30249872
Gal3 expression in regional lymph nodes might be associated with oral squamous cell carcinomas progression. The increased Gal3 expression in regional lymph nodes of larger tumors underlines the need of immunomodulatory treatment concepts in early-stage oral squamous cell carcinomas . Blocking of Gal3 might be a therapeutic option in oral cancer. PMID: 30115022
High Gal-3 serum levels predict fibrosis of the atrial appendage. PMID: 28079145
this study reviews the role of galectin-3 in Atrial Fibrillation mechanisms and its potential therapeutic implications. PMID: 29587379
Our findings provide evidence that allele C of rs4652 and allele T of rs11125 in the galectin-3 gene may be risk factors for cervical cancer. PMID: 28848207
High GAL-3 expression is associated with Salivary Gland Tumor. PMID: 29580041
Galectin-3 is greatly reduced in patients with cutaneous lupus lesions compared with healthy controls, which may contribute to the recruitment of inflammatory cells in the skin. PMID: 29058991
Progesterone receptor, EGFR, and galectin-3 are expressed differentially in uterine smooth muscle tumors. PMID: 29729689
Galectin-3 belongs to a class of inflammatory mediators that is associated with the degree of myocardial inflammation and fibrosis. It is related to the severity of myocardial ischemia and is negatively correlated with the cardiac ejection fraction. PMID: 29287900
Increased GAL-3 levels are an independent predictor of all-cause mortality in hemodialysis patients. PMID: 26787685
High GAL3 expression is associated with oral squamous cell carcinomas. PMID: 29284429
High expression level of Galectin-3 and low expression level of TRAIL were found to be positively correlated with the shorter median survival time and overall survival time. PMID: 28925481
Galectin-3 is overexpressed in patients with thyroid nodules, and can be used for diagnostic imaging and therapeutic targeting of cancer patients. (Review) PMID: 29393868
With emerging evidence to support the function and application of galectin3, the current review aims to summarize the latest literature regarding the biomarker characteristics and potential therapeutic application of galectin3 in associated diseases. PMID: 29207027
Our results indicate that concomitant stimulation and colocalization of galectin-3 with CD147 are associated with increased gelatinolytic activity in the actively ulcerating human cornea PMID: 29340650
Galectin-3 can be used as a biomarker for the prognosis evaluation of acute heart failure, and its combined analysis can increase the predictive value of NT-proBNP PMID: 29077153
Galectin has been identified as a proinflammatory protein and modulates immune responses either as damage-associated molecular patterns or as pattern recognition receptors. PMID: 28828226
Gal-3 was found to be significantly higher in the stroma of patients with H. pylori infection, mainly on Cag-A positive H. pylori, with chronic gastritis. PMID: 28939284
The present study demonstrates a relationship between galectin-3 levels and total body fat, abdominal fat, body fat distribution, cardiac size and geometry, and increase in total body fat over 2 years in young children. PMID: 29327139
Results suggest that galectin-3 could help to monitor the risk of short-term mortality in unselected patients with acute heart failure (AHF) attended in the emergency department (ED). PMID: 28406038
Report establishes the functional significance of Gal-3 as a broad-spectrum upstream effector in osteoarthritis (OA). A positive correlation between cartilage degeneration and Gal-3 positivity in chondrocytes and the ECM was found. PMID: 27982117
the secretion of galectin-3 as a novel mechanism for osteoblasts to control osteoclastogenesis and to maintain trabecular bone homeostasis independently of the RANKL/OPG-axis. PMID: 28822790
Gal-3 plasma concentration was significantly higher in pulmonary arterial hypertension patients. PMID: 28826890
Galectin-3 was associated with incident ischaemic stroke in younger but not older individuals. PMID: 28872212
As MUC1 and galectin-3 are both commonly overexpressed in most types of epithelial cancers, their interaction and impact on EGFR activation likely makes important contribution to EGFR-associated tumorigenesis and cancer progression. PMID: 28731466
serum Gal-3 is increased in Acute exacerbation of chronic obstructive pulmonary disease patients. PMID: 28947730
High serum levels of galectin-3 were found in patients with schizophrenia compared with that in controls. PMID: 28698921
N-linked glycoprotein maturation is not required for Gal-3 transport from the cytosol to the extracellular space, but is important for cell surface binding. Additionally, secreted Gal-3 is predominantly free and not packaged into extracellular vesicles. These data support a secretion pathway independent of N-linked glycoproteins and extracellular vesicles. PMID: 28775154
NRG1 and Gal-3 were significantly more elevated in cancer patients than in healthy controls. PMID: 28430337
discovery of site specific N-glycosylation changes of LGALS3BP in association of PDAC may provide useful clues to facilitate cancer detection or phenotype stratification PMID: 28627758
Our findings establish gal-3 as a molecular regulator of the JAG1/Notch-1 signaling pathway and have direct implications for the development of strategies aimed at controlling tumor angiogenesis. PMID: 28533486
findings reveal that differential levels of Gal-3 and Gal-8 expression and recruitment to Group A streptococcus (GAS) between epithelial cells and endothelial cells may contribute to the different outcomes of GAS elimination or survival and growth of GAS in these two types of cells. PMID: 28743815
The methylation frequency of the galectin-3 promoter was significantly higher while galectin-3 mRNA was lower in acute-on-chronic hepatitis B liver failure (ACHBLF) than in chronic hepatitis B and healthy controls. The results suggest that hypermethylation of the galectin-3 promoter might be an early biomarker for predicting disease severity and prognosis in patients with ACHBLF. PMID: 28185839
Serum Gal-3 and Nox4 levels were significantly elevated and correlated in 26 human pulmonary arterial hypertension patients when compared with 14 age- and sex-matched healthy controls. PMID: 28431936
These results demonstrate Tsc2-deficient mesenchymal progenitors cause aberrant morphogenic signals, and identify an expression signature including Lgals3 relevant for human disease of TSC1/TSC2 inactivation and mTORC1 hyperactivity. PMID: 28695825
Galectin-3 is a possible immunological target molecule of the pathogenic auto-antibodies PMID: 27339072

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.